


Ask a doctor about a prescription for ILVIGRIP NOCHE JARABE (Syrup)
Package Leaflet: Information for the User
IlviGrip Noche Syrup
paracetamol/dextromethorphan/doxylamine
Read all of this leaflet carefully before you start taking this medicinebecause it contains important information for you
Follow the instructions for administration of the medicine contained in this leaflet or as indicated by your doctor or pharmacist.
Contents of the Package Leaflet:
5 Conservation of IlviGrip Noche
IlviGrip Noche is an association of paracetamol, dextromethorphan hydrobromide, and doxylamine succinate.
It is indicated in adults and adolescents from 12 years of age for the symptomatic relief of the common cold and flu that present with pain or fever, nasal congestion, and unproductive cough (irritative cough, nervous cough). It is especially indicated for nighttime treatment.
You should consult a doctor if your symptoms worsen or do not improve after 3 days of treatment.
Do not take IlviGrip Noche
Warnings and precautions
This medicine can cause dependence. Therefore, treatment should be short-term.
Consult your doctor or pharmacist before taking IlviGrip Noche:
During treatment with IlviGrip Noche, inform your doctor immediately if:
Patients with the following conditions should consult a doctor before taking this medicine:
Other medications and paracetamol
Inform your doctor or pharmacist if you are taking:
People over 65 years of age should consult their doctor before taking this medicine due to their greater sensitivity to the appearance of side effects.
There have been cases of abuse with medications containing dextromethorphan by adolescents, so this possibility should be taken into account, as serious side effects can occur (see section: If you take more IlviGrip Noche than you should).
Serotonin syndrome:
Serotoninergic effects have been reported, including the development of a potentially life-threatening serotonin syndrome for dextromethorphan with concomitant administration of serotoninergic agents, such as selective serotonin reuptake inhibitors (SSRIs), medications that impair serotonin metabolism (including monoamine oxidase inhibitors (MAOIs) and CYP2D6 inhibitors).
The serotonin syndrome can include changes in mental status, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. If serotonin syndrome is suspected, treatment with IlviGrip Noche should be discontinued.
Interference with analytical tests
If you are going to have any analytical tests (including blood tests, urine tests, etc.), inform your doctor that you are taking this medicine, as it may alter the results.
Doxylamine succinate may interfere with skin allergy tests that use allergens. It is recommended to discontinue treatment with IlviGrip Noche at least 3 days before starting such tests.
Paracetamol may alter the values of analytical determinations of uric acid and glucose.
Children and adolescents
This medicine is contraindicated in children under 12 years of age.
Taking IlviGrip Noche with other medications
Inform your doctor or pharmacist that you are taking, have recently taken, or may need to take any other medication, as many other medications can affect liver function and increase the risk of liver toxicity.
Before starting to take this medicine, consult your doctor if you are using any of the following medications, as it may be necessary to modify the dose of one of them or interrupt treatment:
Do not take this medicine during treatment or in the 2 weeks following treatment with the following medications, as serious side effects can occur, characterized by excitement, high blood pressure, and fever above 40°C (hyperpyrexia):
Taking IlviGrip Noche with food, drinks, and alcohol
The use of paracetamol in patients who habitually consume alcohol (3 or more alcoholic beverages per day) can cause liver damage.
Alcoholic beverages should not be consumed during treatment, as they can increase the adverse effects and cause drowsiness during the day.
Do not take this medicine with grapefruit or bitter orange juice, as they can increase the adverse effects of this medicine.
Taking this medicine with food, except for the aforementioned, does not affect its efficacy.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
The influence on the ability to drive and use machines is moderate. This medicine can cause drowsiness, sedation, or blurred vision, so if you experience these symptoms, you should not drive or operate machines.
IlviGrip Noche contains sucrose
This medicine contains sucrose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
Patients with diabetes mellitus should note that this medicine contains 8.250 g of glucose per 30 ml of syrup.
IlviGrip Noche contains propylene glycol
This medicine contains 3000 mg of propylene glycol per adult dose of 30 ml of syrup. It can produce symptoms similar to those of alcohol and may decrease the ability to drive or operate machinery. If you have liver or kidney disease, do not take this medicine unless your doctor recommends it. Your doctor may perform additional checks while you are taking this medicine.
IlviGrip Noche contains sodium benzoate
This medicine contains 30 mg of sodium benzoate per adult dose of 30 ml of syrup.
IlviGrip Noche contains sodium
This medicine contains 75.2 mg of sodium. Patients on low-sodium diets should note that this medicine contains 75.2 mg of sodium (3.268 mmol) per 30 ml of syrup, equivalent to 3.8% of the maximum daily recommended intake by the WHO of 2 g of sodium for an adult.
Follow the administration instructions of the medicine contained in this prospectus or as indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist. Do not take this medicine if you have already taken 4 doses of medicines containing paracetamol during the day.
The recommended dose is:
Adults and adolescents from 12 years of age:
Take 30 ml of syrup, administered with the dosing cup, once a day, before bedtime.
This medicine is taken orally.
Shake well before use.
Do not exceed the recommended dose.
If symptoms worsen or persist after 3 days of treatment, consult your doctor or pharmacist.
Exceeding the recommended dose can cause liver damage, especially with the concomitant use of other medicines containing paracetamol. Do not take IlviGrip Noche if you have already taken 4 doses of other medicines containing paracetamol during the day. In case of doubt, consult your doctor or pharmacist. This medicine is not designed for long-term use. If your symptoms worsen or do not improve after 3 days, or if you have a high fever, consult your doctor or pharmacist.
Use in children and adolescents
This medicine is contraindicated in children under 12 years of age.
If you take more IlviGrip Noche than you should
It contains paracetamol. You should consult your doctor or pharmacist immediately. Taking too much paracetamol can cause serious liver damage.
If you take more IlviGrip Noche than indicated, you may experience the following symptoms: dizziness, nausea and vomiting, involuntary muscle contractions, agitation, confusion, drowsiness, disorders of consciousness, involuntary eye movements, cardiac disorders (acceleration, increase or alteration of heart rate), hyperthermia, coordination disorders, psychosis with visual hallucinations and hyperexcitability, loss of appetite, yellowing of the skin and eyes (jaundice), abdominal pain, excitability, restlessness, nervousness and irritability, depression or stimulation of the central nervous system, anticholinergic effects (dilated pupils, fever, dry mouth, decrease in intestinal tone), redness, increase or decrease in blood pressure, alteration of gait, dizziness, irritability, sedation, and hallucinations. Delirium, decreased respiration, loss of consciousness, and death may occur. A serious complication can be rhabdomyolysis (muscle damage), followed by kidney failure. More severe symptoms may appear after a massive overdose.
Other symptoms in case of massive overdose may be: coma, severe respiratory problems, and convulsions.
Contact your doctor or hospital immediately if you experience any of the mentioned symptoms.
There have been cases of abuse with medicines like IlviGrip Noche that contain dextromethorphan, which can cause serious adverse effects such as: anxiety, panic, memory loss, tachycardia(acceleration of heartbeats), lethargy, hypertension or hypotension (high or low blood pressure), mydriasis (pupil dilation), agitation, vertigo, gastrointestinal disorders, slurred speech, nystagmus (involuntary and uncontrolled eye movement), fever, tachypnea (shallow and rapid breathing), brain damage, ataxia (uncoordinated movements), convulsions, respiratory depression, loss of consciousness, arrhythmias (irregular heartbeats), and death.
If you have ingested an overdose and experience any of the above symptoms, you should go immediately to a medical center, even if you do not notice the symptoms, since they often do not manifest until 3 days after ingestion of the overdose, even in cases of severe poisoning.
Treatment of overdose is most effective if started within 4 hours after ingestion of the medicine.
Patients being treated with barbiturates or chronic alcoholics may be more susceptible to the toxicity of a paracetamol overdose.
In case of overdose or accidental ingestion, go immediately to a medical center or call the Toxicology Information Service (phone: 91 562 04 20), indicating the medicine and the amount ingested.
Pediatric population
Severe adverse effects can occur in children in case of overdose, including neurological disorders. Caregivers should not exceed the recommended dose.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking the product and contact your doctor immediately if you notice:
Possible side effects of IlviGrip Noche may be:
During the use of IlviGrip Noche, the following adverse effects have been observed, whose frequency cannot be established with precision:
People over 65 years of age have a higher risk of suffering from adverse reactions, as they may have other diseases or may be taking other medicines simultaneously. These people also have a higher risk of suffering a fall.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep in the perfectly closed case to protect it from light.
.
Discard 1 year after opening the bottle for the first time.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the bottle after CAD. The expiration date is the last day of the month indicated.
Medicines should not be thrown away through the sewers or in the trash. Deposit the packaging and medicines that are no longer needed in the SIGRE point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This way, you will help protect the environment.
Composition of IlviGrip Noche
Appearance of the product and package contents
IlviGrip Noche Syrup is presented as a clear green, slightly viscous liquid, with an anise flavor and aroma.
It is presented in a glass bottle with a child-resistant cap.
The medicine is presented in bottles of 90 ml, 120 ml, and 180 ml with a polypropylene dosing cup with a 30 ml graduation.
Marketing authorization holder
LABORATORIOS VICKS S.L.
Avda. de Bruselas, 24
28108 - Alcobendas (Madrid)
Spain
Local representative
PROCTER & GAMBLE ESPAÑA S.A.
Avda. de Bruselas, 24
28108 - Alcobendas (Madrid)
Spain
Manufacturer
PROCTER & GAMBLE MANUFACTURING GMBH
Procter & Gamble Strasse, 1 Gross Gerau
D64521
Germany
Date of the last revision of this prospectus: January 2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for ILVIGRIP NOCHE JARABE (Syrup) – subject to medical assessment and local rules.